Nanomedicine-driven molecular targeting, drug delivery, and therapeutic approaches to cancer chemoresistance

•A systematic review on how new generation molecular nanomedicine allows chemoresistant cancer management.•Recent developments in molecular targeting approaches for tumor microenvironment targeted drug delivery.•Clinical progress of nanomedicine driven molecular approach to cure chemoresistant tumor...

Full description

Saved in:
Bibliographic Details
Published in:Drug discovery today 2021-03, Vol.26 (3), p.724-739
Main Authors: Khot, Vishwajeet M., Salunkhe, Ashwini B., Pricl, Sabrina, Bauer, Joanna, Thorat, Nanasaheb D., Townley, Helen
Format: Article
Language:English
Subjects:
Animals
Antineoplastic Agents - administration & dosage
Antineoplastic Agents - pharmacokinetics
Antineoplastic Agents - pharmacology
Drug Delivery Systems
Drug Resistance, Neoplasm
Humans
Molecular Targeted Therapy
Nanomedicine
Neoplasms - drug therapy
Neoplasms - pathology
Tissue Distribution
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•A systematic review on how new generation molecular nanomedicine allows chemoresistant cancer management.•Recent developments in molecular targeting approaches for tumor microenvironment targeted drug delivery.•Clinical progress of nanomedicine driven molecular approach to cure chemoresistant tumor.•Systemic release of tumor targeted chemotherapeutic drugs in response to internal and external triggers/stimuli to induce effective therapeutics by new generation nanoplatforms. Cancer cell resistance to chemotherapeutics (chemoresistance) poses a significant clinical challenge that oncology research seeks to understand and overcome. Multiple anticancer drugs and targeting agents can be incorporated in nanomedicines, in addition to different treatment modalities, forming a single nanoplatform that can be used to address tumor chemoresistance. Nanomedicine-driven molecular assemblies using nucleic acids, small interfering (si)RNAs, miRNAs, and aptamers in combination with stimuli-responsive therapy improve the pharmacokinetic (PK) profile of the drugs and enhance their accumulation in tumors and, thus, therapeutic outcomes. In this review, we highlight nanomedicine-driven molecular targeting and therapy combination used to improve the 3Rs (right place, right time, and right dose) for chemoresistant tumor therapies. Nanomedicines with molecular-targeting functionality ensure the efficient delivery of chemotherapeutic cargoes into the tumor microenvironment to overcome chemoresistance.
ISSN:1359-6446
1878-5832
DOI:10.1016/j.drudis.2020.12.016